Presentation describes survey results on patient and public attitudes to use of patient data for research and related purposes. Presented by Cicely Marston at the Data Management in Practice workshop, which took place at the London School of Hygiene and Tropical Medicine on Nov 14th 2013
Decision makers in the healthcare field like doctors, patients and policy makers need access to clinical evidence to address issues that have bearing on the health of the population and the treatment prescribed and thereby on the financials implications of the healthcare industry.
Decision makers in the healthcare field like doctors, patients and policy makers need access to clinical evidence to address issues that have bearing on the health of the population and the treatment prescribed and thereby on the financials implications of the healthcare industry.
The global precision medicine market has benefitted greatly from advancements in the life science industry. Although in its nascent stage, targeted therapies hold high chances of becoming a massive success in the coming years because of the potential to treat and cure chronic illnesses. The market is thus expected to expand at a compound annual growth rate (CAGR) of 11.60% between 2018 and 2023, generating USD 88.25 Bn in revenue by 2023.
Precision Medicine is now a funded NIH initiative and an organic movement in the clinic and at the research institute. Based on work with Genomics England, multiple large pharmaceutical firms, and research hospitals, attendees will learn about the best practices for epidemiology, signal detection, research, and the clinical diagnostics associated with Precision Medicine, including the development of high-scale bio-repositories that link traditional patient data with genomic information. Come hear about how leadership, collaboration, consent, and compute can lead to success or failure in your Precision Medicine initiative, and how to bring your stakeholders together for an aligned mission response.
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
Personalised medicine holds great promised for both improving patients’ outcomes and enhancing the efficiency of treatment. Medicines paired with diagnostics are the backbone of personalised medicine, presenting new challenges in for health technology assessment. The situation in England, particularly how NICE might respond to this challenge, was the focus of the third networking event co-sponsored by the Association of the British Pharmaceutical Industry association (ABPI) and the British In Vitro Diagnostics Association. At this one-day event, speakers set the stage for discussion by presenting defining the context of this challenge for England.
OHE’s Adrian Towse presented on the economics. He discussed the elements of value of a diagnostics test (see our earlier blog post) and described the context necessary to produce useful assessments and to ensure subsequent use in the marketplace. His topics included issues of evidence generation, incentives for innovation, flexible approaches to access coincident with evidence development, and encouraging uptake and use.
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...Office of Health Economics
The Biotherapy Development Association convened a two-day workshop in January 2014 to assess access to innovative cancer medicines in Europe. This presentation by OHE's Adrian Towse covers the situation in England, examining challenges that are peculiar to England as well as the English experience with issues common across countries.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
Overview of the Patient-Centered Outcomes Research Institute (PCORI), how PCORI views Patient-Centered Outcomes Research and how this is related to PCORI’s major funding mechanisms.
Since time has changed, the rectification, upgrading and innovation through disruptive ways have become a part of every aspect of our lives. From automobiles to communication every other line of lifestyle has seen an upgrade and so does the medicine
Recent advances in patient engagement in research, including patients’ and advocates’ roles in patient
focused-drug development (PFDD) and patient-reported outcomes (PROs).
Clinical Research Informatics (CRI) Year-in-Review 2014Peter Embi
Peter Embi's review of notable publications and events in the field of Clinical Research Informatics (CRI) that took place in 2013+. This was presented as the closing keynote presentation of the 2014 AMIA CRI Summit in San Francisco, CA on April 11, 2014.
The global precision medicine market has benefitted greatly from advancements in the life science industry. Although in its nascent stage, targeted therapies hold high chances of becoming a massive success in the coming years because of the potential to treat and cure chronic illnesses. The market is thus expected to expand at a compound annual growth rate (CAGR) of 11.60% between 2018 and 2023, generating USD 88.25 Bn in revenue by 2023.
Precision Medicine is now a funded NIH initiative and an organic movement in the clinic and at the research institute. Based on work with Genomics England, multiple large pharmaceutical firms, and research hospitals, attendees will learn about the best practices for epidemiology, signal detection, research, and the clinical diagnostics associated with Precision Medicine, including the development of high-scale bio-repositories that link traditional patient data with genomic information. Come hear about how leadership, collaboration, consent, and compute can lead to success or failure in your Precision Medicine initiative, and how to bring your stakeholders together for an aligned mission response.
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
Personalised medicine holds great promised for both improving patients’ outcomes and enhancing the efficiency of treatment. Medicines paired with diagnostics are the backbone of personalised medicine, presenting new challenges in for health technology assessment. The situation in England, particularly how NICE might respond to this challenge, was the focus of the third networking event co-sponsored by the Association of the British Pharmaceutical Industry association (ABPI) and the British In Vitro Diagnostics Association. At this one-day event, speakers set the stage for discussion by presenting defining the context of this challenge for England.
OHE’s Adrian Towse presented on the economics. He discussed the elements of value of a diagnostics test (see our earlier blog post) and described the context necessary to produce useful assessments and to ensure subsequent use in the marketplace. His topics included issues of evidence generation, incentives for innovation, flexible approaches to access coincident with evidence development, and encouraging uptake and use.
Rationale and Procedure for Oncology Pricing and Reimbursement in England Tow...Office of Health Economics
The Biotherapy Development Association convened a two-day workshop in January 2014 to assess access to innovative cancer medicines in Europe. This presentation by OHE's Adrian Towse covers the situation in England, examining challenges that are peculiar to England as well as the English experience with issues common across countries.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
Overview of the Patient-Centered Outcomes Research Institute (PCORI), how PCORI views Patient-Centered Outcomes Research and how this is related to PCORI’s major funding mechanisms.
Since time has changed, the rectification, upgrading and innovation through disruptive ways have become a part of every aspect of our lives. From automobiles to communication every other line of lifestyle has seen an upgrade and so does the medicine
Recent advances in patient engagement in research, including patients’ and advocates’ roles in patient
focused-drug development (PFDD) and patient-reported outcomes (PROs).
Clinical Research Informatics (CRI) Year-in-Review 2014Peter Embi
Peter Embi's review of notable publications and events in the field of Clinical Research Informatics (CRI) that took place in 2013+. This was presented as the closing keynote presentation of the 2014 AMIA CRI Summit in San Francisco, CA on April 11, 2014.
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...Efe Clement Abel
Abstract: Adherence is the quantified level to which an individual follows a prescribed treatment and a low level of adherence to antiretroviral therapy(ART) adversely affects a patient’s treatment outcome and results in a rebound of plasma viraemia, development of resistant strains of HIV, more rapid immune deterioration, development of AIDS and death. This study is aimed at assessing the level of adherence to ART among HIV-positive patients assessing care in Central Hospital, Warri, Delta State, Nigeria. A descriptive cross-sectional study. Data were obtained using a semi-structured, interviewer-administered questionnaire and analysed using SPSS version 23. A total of 303 persons were recruited for the study. The mean age of respondents was 36.2±10.8years. Less than half of the subjects (45.5%) were adherent to their ART. Among the non-adherent subjects, the common reasons reported for missing doses of ART were forgetfulness (50.9%), too busy with other things (43.6%) and away from home (35.8%). This study showed that adherence to ART among the study population was poor. Forgetfulness, too busy with other things and being away from home were the most common reason for non-adherence. It is, therefore, recommended that; regular health education should be organised for HIV patients on ART on the importance of being adherent to their ART, regular assessment of adherence to ART should be carried out and a method of reminding patients who are non-adherent to ART on the need to take their ART as at when due should be considered as part of the routine services provided by ART centres.
Replies DB 6 W121-Related to this post httpswww.homewor.docxcarlt4
Replies DB 6 W12
1-Related to this post
https://www.homeworkmarket.com/questions/db-6-w-12-research
Professor question
-Great explanation. What do you think, would be some strategies in achieving the desired population or sample analysis? Thanks.
-peer. replies
2-Michael
A researchable population is a critical element in conducting any investigative study; it entails to the people and objects that are isolated, taken into account, and focused upon for scientific data collection (Ritchie, Lewis, Nicholls, & Ormston, 2013). However, due to large masses of a population, the investigator cannot test all people because of the expenses and time consumed. Hence there is the use of the sampling technique. Such a sampling technique often has similar traits or characteristics. There are two types of researchable populations used in a study which are; target population and accessible population.
The most suitable research populace would be the accessible population. Accessible population is the part of the mass in which the investigator has reasonable and full access and can apply their conclusions. It is a subset of the target method, which refers to a researcher taking an entire scale of people to generalize and draw conclusions.
There are several challenges experienced in sampling in a population. The common problem is that researcher mainly focuses on the high-frequency values and patterns and end up not considering the lower level. Such ignorance makes the researcher miss out on blocks of data. Additionally, investigators assume that concepts are uniformly similar and distributed all over the population and over a specified periodime ("challenges in sampling," 2019).
3-Katiana
The most appropriate researchable population for use within my research project would be of patients seeking health care options who are facing a number of debilitating illnesses and diseases some of which require a great deal of care that involve the use of “minimally invasive procedures like minithoracotomy and small port access and the continuing use of newer measures like percutaneous methods to address valvular heart disease" (Rosengart, 2008) Some of the existential challenges in obtaining a sample from this population includes some of the rudimentary and basic facts like they are not all going to be congregated in one particular area unless there is a hospital that deals with specialized care for these individuals that need this type of health care as an option. Additionally gathering data that is representative of this population may be also difficult due to privacy restrictions that govern health care and healthcare administration. Some participants may ultimately refuse to partake or play a role in the process as they may be of the belief that there rights to privacy are being violated. Moreover research will also need to be conducted and gathered on the health care group facing these occupationals risks and this may be hard to gather because the.
Early diagnosis and prevention enabled by big data geneva conference finale-Marefa
The presentation provides an overview of how digital health or use of data processing and telecommunication infrastructure can contribute to the early diagnosis and prevention of diseases.
Simon Denegri - Public involvement in CLAHRCsCLAHRC-NDL
Simon Denegri (INVOLVE chair and NIHR National Director for Public Participation and Engagement in Research) keynote presentation at NIHR CLAHRC East Midlands launch event on 14 February 2014, Loughborough.
To evaluate the benefits of Structured Medication Reviews in elderly Chinese ...Health Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, To evaluate the benefits of Structured Medication Reviews in elderly Chinese patients, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Cihr guest presentation and webinar afternoon talk - january 2014Simon Denegri
Presentation on public involvement and engagement in health research: why, how and what next? Given to the staff of the Canadian Institutes for Health Research (CIHR), Ottawa, Canada, 2014
Similar to Using NHS Electronic Health Records for Research (20)
This is a presentation given to final year doctoral students at the London School of Hygiene & Tropical Medicine. It covers issues pertaining to copyright and open access publishing that students need to consider before submitting their thesis, as well as information on research data management and the actual process of submission.
Presentation slides on Open Science and research reproducibility. Presented by Gareth Knight (LSHTM Research Data Manager) on 18th September 2018, as part of an Open Science event for LSHTM Week 2018.
Laurence Horton of the London School of Economics gave a talk on the information security implications of the General Data Protection Regulation (GDPR). Presented at the London Area Research Data meeting on 17th November 2017, held at the London School of Hygiene & Tropical Medicine.
An introduction to the General Data Protection Regulation (GDPR) and its implications for research data management. Presentation given by Tim Rodgers of Imperial College London at the London Area Research Data meeting, held at the London School of Hygiene & Tropical Medicine on 17th Nov 2017.
Report on key findings of a Wellcome-commissioned study to investigate current practices for paper, data & code sharing among Wellcome & ESRC funded researchers and any barriers that are encountered. Presented by Gareth Knight at a CPD25 Open Access workshop at the Foundling museum in London on 26 April 2017.
Presentation slides from a talk by Gareth Knight which discussed the need to consider data sharing activities in academic citizenship, different approaches that may be taken to publish data associated with publications, and the opportunities presented by data journals
Presentation by Chris Grundy of LSHTM which describes his use of satellite images for population estimation and surveys, as well as mapping work performed by the online mapping community and NGOs to improve crowd sourced mapping data.
Ketevan is a Research Fellow in the Department of Health Services Research and Policy at LSHTM. She currently works on SPOTLIGHT, a cross-European research project for sustainable prevention of obesity through integrated strategies, where she is managing a large-scale survey conducted in England to assess the perceptions of environmental obesogenicity in selected neighbourhoods. She also assessed the built environment in those neighbourhoods using remote imaging using Google Street View.
An overview of the i-Sense platform, developed by UCL to monitor the spread of infectious disease. Presented by Jens Geyti of University College London at LSHTM's 'Enhancing data capture in health research' RDM event on November 20th, 2015.
Case study on the FluSurvey platform, developed by the London School of Hygiene & Tropical Medicine. Presented by Dr Sebastian Funk at LSHTM's 'Enhancing data capture in health research' RDM event on November 20th, 2015.
Case study on the development of the MyHeart Counts app built using Apple’s ResearchKit platform and future plans for Android development. Presented by Dr Dario Salvi of University of Oxford at LSHTM's 'Enhancing data capture in health research' RDM event on November 20th, 2015.
Case study on the use of electronic data collection in a modular household survey as part of the IDEAS project. Presented by Keith Tomlin at LSHTM's 'Enhancing data capture in health research' RDM event on November 20th, 2015.
Case study on mobile-based experience sampling using the Q-Sense and EmotionSense platform. Presented by Dr. Neal Lathia of Cambridge University at LSHTM's 'Enhancing data capture in health research' RDM event on November 20th, 2015.
An introduction to the FAIR principles and a discussion of key issues that must be addressed to ensure data is findable, accessible, interoperable and re-usable. The session explored the role of the CDISC and DDI standards for addressing these issues.
Presented by Gareth Knight at the ADMIT Network conference, organised by the Association for Data Management in the Tropics, in Antwerp, Belgium on December 1st 2015.
Presentation by Angus Whyte of the Digital Curation Centre. It was presented at the LSHTM Research Data Services workshop on June 30th 2015, an event organised to mark the end of LSHTM's Wellcome Trust funded RDM project. Updated version added on 14th August to clarify graph labels.
Presentation by Sally Rumsey of the University of Oxford. It was presented at the LSHTM Research Data Services workshop on June 30th 2015, an event organised to mark the end of LSHTM's Wellcome Trust funded RDM project.
Presentation by Stuart Lewis of the University of Edinburgh. It was presented at the LSHTM Research Data Services workshop on June 30th 2015, an event organised to mark the end of LSHTM's Wellcome Trust funded RDM project.
Presentation by Jeremy Barraud & Jess Crilly of University of the Arts London. It was presented at the LSHTM Research Data Services workshop on June 30th 2015, an event organised to mark the end of LSHTM's Wellcome Trust funded RDM project.
More from London School of Hygiene and Tropical Medicine (20)
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Using NHS Electronic Health Records for Research
1. Using NHS Electronic Health Records for
research: results from a survey on
patient and public attitudes
Cicely Marston
Chrysanthi Papoutsi, Julie Reed, Azeem Majeed, Derek Bell
14 November 2013, LSHTM
2. Background
• Electronic Health Record (EHR): ‘longitudinal electronic record
of an individual that contains data from multiple EMRs and
EPRs; shared and interoperable across settings’ (Singleton et
al., 2007, p. 19).
o Used for health, research and policy/planning purposes simultaneously.
• Tensions between wider health information sharing and privacy
protection.
• Wealth of research on patient views, but little large-scale work
on integrated EHRs simultaneously used for different purposes.
4. Quantitative component
• Large-scale cross-sectional questionnaire survey with a total of
5,331 participants (85.5% response rate).
• Stratified cluster random sample of patients and members of the
public in an area of West London, UK.
• Recruitment in 8 outpatient waiting areas of a teaching hospital
and the waiting rooms of 8 general practice (GP) surgeries within
the hospital catchment area over a 6-week period from 1 August
2011.
• 2,554 respondents (48%) included in the full analysis sample for
research-related variables.
5. Characteristics
Age category
18-24
25-34
35-44
45-54
55-64
65-74
75+
Gender
Female
Male
Ethnicity
White British
White Non-British
Black/African/Caribbean/British Black
Asian/Asian British
Other ethnic group
Educational qualifications
No academic qualification
GCSE
A-Levels
Vocational qualification
Degree
Higher Degree
N (%)
203 (7.9)
703 (27.5)
542 (21.2)
400 (15.7)
296 (11.6)
250 (9.8)
160 (6.3)
1,521 (59.6)
1,033 (40.4)
1,447 (56.7)
524 (20.5)
182 (7.1)
188 (7.4)
213 (8.3)
111 (4.3)
278 (10.9)
255 (10.0)
304 (11.9)
959 (37.5)
647 (25.3)
Characteristics
Long term conditions
None
At least one condition
Frequency of healthcare use in past 6 months
0 to 2
3 to 5
6 to 9
10 plus
Number of different healthcare services visited
0-1
2
3+
Satisfaction with the NHS
Very satisfied
Satisfied
Neither satisfied or dissatisfied
Dissatisfied or very dissatisfied
Previous participation in health research
No
Yes
Recruitment site
GP
Outpatient
Total
N (%)
916 (35.9)
1,638 (64.1)
914 (35.8)
895 (35.0)
419 (16.4)
326 (12.8)
844 (33.0)
868 (34.0)
842 (33.0)
714 (28.0)
1,390 (54.4)
304 (11.9)
146 (5.7)
2,090 (81.8)
464 (18.2)
859 (33.6)
1,695 (66.4)
2,554 (100)
6. Overall support and concerns
Security concerns
Overall support for integrated EHRs
100%
100%
78.8%
63.6%
27.1%
21.2%
9.3%
0%
0%
In favour
Undecided
Against
Yes
No
7. Patient views
EHRs for research
EHRs for healthcare
100%
100%
100%
90%
90%
90%
80%
80%
EHRs for planning and
policy
80%
70%
67.3%
68.5%
70%
70%
60%
60%
50%
50%
50%
40%
40%
40%
30%
30%
61.0%
60%
30%
23.1%
20%
9.6%
10%
20%
13.4%
18.2%
Complete
record
Partial record
Neither
20.0%
19.0%
10%
10%
0%
20%
0%
0%
With identifiersWithout identifiers
Neither
With identifiers
Without
identifiers
Neither
Also see: Luchenski, S.A., Reed, J.E., Marston, C., Papoutsi, C., Majeed, A., Bell, D. (2013). Patient and
Public Views on Electronic Health Records and Their Uses in the United Kingdom: Cross-Sectional
Survey. J Med Internet Res, 15(8):e160. URL: http://www.jmir.org/2013/8/e160/
8. Access preferences
NHS researchers
12.8%
Academic researchers
67.7%
9.8%
19.5%
65.9%
24.3%
With identifiers
Without identifiers
Health charities
Drug companies
8.1%
59.0%
6.3%
0%
49.6%
10%
20%
30%
Not at all
32.9%
44.1%
40%
50%
60%
70%
80%
90%
100%
9. Multivariable analysis: EHRs for research
More likely to support use of
identifiable information, than
without identifiers:
• Older age groups (65+)
• Males
• Ethnic background other than
White British
• Education levels lower than
higher degree
• Frequent health service users
Identifiable EHRs for research
(base: without identifiers)
Adjusted RR
95% CI
P-value
Age (base: 25-34)
65-74
2.54
[1.84,3.52]
0.00
75+
2.44
[1.48,4.02]
0.00
1.35
[1.04,1.75]
0.03
Sex (base: female)
Male
Ethnicity (base: White British)
White non-British
1.55
[1.05,2.29]
0.03
Black British
2.09
[1.37,3.18]
0.00
Asian British
1.68
[1.13,2.51]
0.01
Education (base: higher degree)
None
4.61
[3.05,6.99]
0.00
GCSE
2.09
[1.60,2.72]
0.00
A-level
1.86
[1.39,2.47]
0.00
Vocational
2.57
[1.59,4.15]
0.00
Degree
1.33
[0.99,1.79]
0.06
Frequency of healthcare visits in the past 6m (base: 0-2 visits)
6-9 visits
1.32
[1.00,1.74]
0.05
10+ visits
1.78
[1.19,2.65]
0.01
10. Multivariable analysis: EHRs for research
More likely to report being against any sharing
of their records for research purposes, rather
than sharing without identifiers:
• Lower education levels
• Very frequent healthcare users
• Those visiting less types of health services
• Those less satisfied with the NHS
• Those recruited in outpatient clinics
No access to EHRs for research
(base: without identifiers)
Adjusted RR
95% CI
P-value
Education (base: higher degree)
None
2.27
[1.05,4.87]
0.04
GCSE
2.27
[1.60,3.20]
0.00
A-level
1.44
[1.03,2.01]
0.03
[1.06,1.69]
0.01
Recruitment site (base: GP clinic)
Outpatient clinic
1.34
Frequency of healthcare visits in the past 6m (base: 0-2 visits)
10+ visits
1.97
[1.24,3.11]
0.00
Types of healthcare services visited in the past 6 m (base: 2 services)
Less likely to report being against any sharing
of their records for research purposes, rather
than sharing without identifiers:
• Those with previous participation in health
research
0-1 services
1.30
[1.03,1.65]
Satisfaction with the NHS (base: very satisfied)
Neither satisfied or
1.41
[1.14,1.74]
dissatisfied
Dissatisfied or very
1.87
[1.23,2.85]
dissatisfied
Previous participation in research (base: No)
Yes
0.74
[0.56,0.98]
0.03
0.00
0.00
0.04
11. Multivariable analysis: research user groups
Similar patterns for access by different user groups:
- Individuals who were more likely to say they would allow access to
their identifiable, compared with anonymised data.
-
Older age
Men
Non-white-British
Lower education levels
- People with no academic qualifications compared with higher
degrees more likely to agree with access to their identifiable
information (RR=3.89 for NHS researchers, RR=4.67 for academic
researchers, RR=11.63 for health charities, RR=10.19 for drug
companies, p=0.00 in all cases).
12. Multivariable analysis: research user groups
- Non-White-British respondents were much more likely to say they
would not allow any access at all than to share their
anonymised data for research.
13. Consent preferences
• Before use of identifiable records: Around 91% would prefer
to be asked for permission against 9% who would not like to
be asked.
• Before use of records without identifiers: Around 54% would
prefer to be asked for permission against 46% who would not
like to be asked.
14. Conclusions
• There is support for integrated EHRs, with accompanying
security concerns.
• Preferences for research access to EHRs are nuanced.
• There are clear differences in preferences by ethnic group
and by education level, which need to be understood
further.
• Any database needs to be developed and used sensitively,
taking into account all concerns, not simply those of the
majority group.
15. Acknowledgments
• All participants
• GP practices and outpatient clinics, patient
organisations, health professionals, and
everyone else who contributed to
recruitment.
• Fiona Riordan
• Serena Luchenski
• Kaori Sasaki
• Anjali Balasanthiran
• Rachael Aldersley
• Cameron Bell
• Sylvia Chalkley
• Jason Curran
• Shaun D’Souza
•
•
•
•
•
•
•
•
Stuart Green
Sarah Hancox
Sina Iqbal
Uzoma Nnajiuba
Harsita Patel
Joshua Wolrich
Jade Zhao
This research was funded by the Wellcome
Trust.
• Julie Reed and Derek Bell are supported by
NIHR CLAHRC for Northwest London, and
Julie Reed is also supported by the Health
Foundation.